Browse the full management transaction log of Novonesis (Novozymes A/S), a publicly traded company based in Denmark. Shares are quoted on DK DK, under the oversight of Finanstilsynet DK. Operating in the Basic Materials sector, Novonesis (Novozymes A/S) has published 28 public disclosures. Market capitalisation: €172.5bn. The latest transaction was reported on 11 November 2021 (Purchase). Among the most active insiders: Unknown. All data is openly available.
28
Insider Decl.
0
Thresholds
·
15 ops.
Buy Volume
€79bn
2 ops.
Sell Volume
Financial data
FY ended December 2025 · cache
370.00 €
Analyst consensus
17 analysts
Buy
362.00 €Target 461.41 €(+25%)560.00 €
Income statement
Revenue4.16 Bn€
Gross profit2.24 Bn€54% margin
Net income583.6 M€14.2% margin
Valuation
PER (trailing)38.7x
PER (forward)21.2x
P/Book2.1x
Beta0.63
Balance sheet & cash
Market cap172.50 Bn€
Total debt1.80 Bn€
Free Cash Flow750.7 M€
Debt / Equity29%
Profitability & ownership
ROE5.4%
ROA3.8%
% insiders15.8%
% institutions31.4%
Last declaration on 11 November 2021
Declarations28 total
Executives●Purchase17DK FSA
U
UnknownCSO and Executive Vice President, Research & Development
Novonesis is a biotechnology company focused on developing enzymatic solutions for various sectors. It is part of Novozymes A/S, a global leader in enzymes and microorganisms.
